SEC Comment Letter for Protara Therapeutics, (TARA) — May 19, 2026
Protara Therapeutics, Inc.
Date: May 19, 2026 · CIK: 0001359931 · Accession: 0000000000-26-005137
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295862
Letter
Re: Protara Therapeutics, Inc. Registration Statement on Form S-3 Filed May 14, 2026 File No. 333-295862 Dear Jesse Shefferman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions.
May 19, 2026
Jesse Shefferman Chief Executive Officer Protara Therapeutics, Inc. 345 Park Avenue South, Third Floor New York, NY 10010
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jennifer Lee, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 19, 2026 Jesse Shefferman Chief Executive Officer Protara Therapeutics, Inc. 345 Park Avenue South, Third Floor New York, NY 10010 Re: Protara Therapeutics, Inc. Registration Statement on Form S-3 Filed May 14, 2026 File No. 333-295862 Dear Jesse Shefferman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jennifer Lee, Esq. </TEXT> </DOCUMENT>